Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma

Inclusion Criteria: * 1-3 intracranial metastases on MRI from melanoma, locally treated with either surgical excision and/or stereotactic irradiation. * Life expectancy of at least 6 months * Aged 18 years or older * WBRT must begin within 8 weeks of completion of localised treatment and within 4 weeks of randomisation * Able to have an MRI brain scan with contrast. Estimated Glomerular Filtrate Rate (eGFR) is adequate at the discretion of the radiologist and capable of having gadolinium-containing contrast medium for MRI as per practice guidelines * Complete localised treatment of all these metastases no more than 6 weeks prior to randomisation * An Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less at randomisation * CT scan of chest, abdomen and pelvis as a minimum prior to randomisation. Scans must be within 12 weeks of randomisation * Serum Lactate Dehydrogenase (LDH) must be = or \< 2 x upper limit of normal * Able to provide written informed consent Exclusion Criteria: * Any untreated intracranial disease * Any previous intracranial treatment (surgical excision and/or stereotactic irradiation treatment and/or WBRT) prior to this diagnosis of intracranial melanoma * Evidence of leptomeningeal disease on pre-local treatment MRI scan * Patients with prior cancers, except: * Those diagnosed more than five years ago with no evidence of disease recurrence within this time; * Successfully treated basal cell and squamous cell skin carcinoma; * Carcinoma in-situ of the cervix * A medical or psychiatric condition that compromises ability to give informed consent or complete the protocol * Positive urine pregnancy test for women of childbearing potential within a week of registration onto the trial